Abstract
Gliomas are a heterogeneous disease both under a clinical and a pathological point of view. The differential expression of genotypic and metabolic alterations presents a regional distribution within the tumor mass. Even the coexistence of different subpopulations of cancer cells, differing in their sensitivity to apoptosis, autophagy and chemotherapy, has been proved in gliomas. Metabolic alterations are important since they confer adaptive, proliferative, and survival advantages on glioma cells. Thereby, metabolic reprogramming provides substrates for biosynthetic pathway, induces apoptosis resistance. The heterogeneous distribution of oxygen within the tumor determines metabolic differences between regions. Glioma cells located at the periphery of the tumor have higher proliferative capacity, which is accompanied by a greater respiration and mitochondrial oxidative capacity compared to cells located at the center of the tumor; such differences could be related to differential degree of hypoxia or oxidative stress between regions of the tumor. Regional differences within glioma have diagnostic and therapeutic implications, and hinder the prediction of the tumor’s biologic aggressiveness and the patient’s response to standard treatment.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Benhar M, Engelberg D, Levitzki A (2002) ROS, stress-activated kinases and stress signaling in cancer. EMBO Rep 3:420–425
Bouzier AK, Voisin P, Goodwin R, Canioni P, Merle M (1998) Glucose and lactate metabolism in C6 glioma cells: evidence for the preferential utilization of lactate for cell oxidative metabolism. Dev Neurosci 20:331–338
Bru A, Albertos S, Luis Subiza J, Garcia-Asenjo JL, Bru I (2003) The universal dynamics of tumor growth. Biophys J 85:2948–2961
Coons SW, Johnson PC (1993) Regional heterogeneity in the DNA content of human gliomas. Cancer 72:3052–3060
Dang CV, Semenza GL (1999) Oncogenic alterations of metabolism. Trends Biochem Sci 24:68–72
Evans SM, Judy KD, Dunphy I, Jenkins WT, Hwang WT, Nelson PT, Lustig RA, Jenkins K, Magarelli DP, Hahn SM, Collins RA, Grady MS, Koch CJ (2004) Hypoxia is important in the biology and aggression of human glial brain tumors. Clin Cancer Res 10:8177–8184
Faivre S, Kroemer G, Raymond E (2006) Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5:671–688
Fantin VR, St-Pierre J, Leder P (2006) Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9:425–434
Fu J, Liu ZG, Liu XM, Chen FR, Shi HL, Pangjesse CS, Ng HK, Chen ZP (2009) Glioblastoma stem cells resistant to temozolomide-induced autophagy. Chin Med J 122:1255–1259
Goldman S, Levivier M, Pirotte B, Brucher JM, Wikler D, Damhaut P, Dethy S, Brotchi J, Hildebrand J (1997) Regional methionine and glucose uptake in high-grade gliomas: a comparative study on PET-guided stereotactic biopsy. J Nucl Med 38:1459–1462
Griguer CE, Oliva CR, Gillespie GY (2005) Glucose metabolism heterogeneity in human and mouse malignant glioma cell lines. J Neurooncol 74:123–133
Hentschel SJ, Sawaya R (2003) Optimizing outcomes with maximal surgical resection of malignant gliomas. Cancer Control 10(2):109–114
Hsu PP, Sabatini DM (2008) Cancer cell metabolism: warburg and beyond. Cell 134:703–707
Ito M, Wakabayashi T, Natsume A, Hatano H, Fujii M, Yoshida J (2007) Genetically heterogeneous glioblastoma recurring with disappearance of 1p/19q losses: case report. Neurosurgery 61:E168–E169
Kaba SE, Kyritsis AP (1997) Recognition and management of gliomas. Drugs 53:235–244
Kang MK, Kang SK (2007) Tumorigenesis of chemotherapeutic drug-resistant cancer stem-like cells in brain glioma. Stem Cells Dev 16:837–847
Kroemer G, Pouyssegur J (2008) Tumor cell metabolism: cancer’s Achilles’ heel. Cancer Cell 13:472–482
Laerum OD, Bjerkvig R, Steinsvag SK, de Ridder L (1984) Invasiveness of primary brain tumors. Cancer Metastasis Rev 3:223–236
Lamborn KR, Chang SM, Prados MD (2004) Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro Oncol 6:227–235
Le Duc G, Peoc’h M, Remy C, Charpy O, Muller RN, Le Bas JF, Decorps M (1999) Use of T(2)-weighted susceptibility contrast MRI for mapping the blood volume in the glioma-bearing rat brain. Magn Reson Med 42:754–761
Lee HC, Kim DW, Jung KY, Park IC, Park MJ, Kim MS, Woo SH, Rhee CH, Yoo H, Lee SH, Hong SI (2004) Increased expression of antioxidant enzymes in radioresistant variant from U251 human glioblastoma cell line. Int J Mol Med 13:883–887
Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL, Yu JS (2006) Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 5:67
Nebeling LC, Miraldi F, Shurin SB, Lerner E (1995) Effects of a ketogenic diet on tumor metabolism and nutritional status in pediatric oncology patients: two case reports. J Am Coll Nutr 14:202–208
Oudard S, Boitier E, Miccoli L, Rousset S, Dutrillaux B, Poupon MF (1997) Gliomas are driven by glycolysis: putative roles of hexokinase, oxidative phosphorylation and mitochondrial ultrastructure. Anticancer Res 17:1903–1911
Rustin P (2002) Mitochondria, from cell death to proliferation. Nat Genet 30:352–353
Santandreu FM, Brell M, Gene AH, Guevara R, Oliver J, Couce ME, Roca P (2008) Differences in mitochondrial function and antioxidant systems between regions of human glioma. Cell Physiol Biochem 22:757–768
Seyfried TN, Mukherjee P (2005) Targeting energy metabolism in brain cancer: review and hypothesis. Nutr Metab 2:30
Shapiro JR, Shapiro WR (1985) The subpopulations and isolated cell types of freshly resected high grade human gliomas: their influence on the tumor’s evolution in vivo and behavior and therapy in vitro. Cancer Metastasis Rev 4:107–124
Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB (2004) Identification of human brain tumour initiating cells. Nature 432:396–401
Sonveaux P, Vegran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN, De Saedeleer CJ, Kennedy KM, Diepart C, Jordan BF, Kelley MJ, Gallez B, Wahl ML, Feron O, Dewhirst MW (2008) Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 118:3930–3942
Walenta S, Wetterling M, Lehrke M, Schwickert G, Sundfor K, Rofstad EK, Mueller-Klieser W (2000) High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res 60:916–921
Zhou S, Kachhap S, Sun W, Wu G, Chuang A, Poeta L, Grumbine L, Mithani SK, Chatterjee A, Koch W, Westra WH, Maitra A, Glazer C, Carducci M, Sidransky D, McFate T, Verma A, Califano JA (2007) Frequency and phenotypic implications of mitochondrial DNA mutations in human squamous cell cancers of the head and neck. Proc Natl Acad Sci USA 104:7540–7545
Acknowledgements
We gratefully acknowledge the support from the Conselleria d’Economia, Hisenda i Innovació del Govern de les Illes Balears and the Fondo de Investigaciones Sanitarias del Ministerio de Sanidad y Consumo del Gobierno Español (PI060266).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Santandreu, F.M., Oliver, J., Roca, P. (2011). Metabolic Differences in Different Regions of Glioma Samples. In: Hayat, M. (eds) Tumors of the Central Nervous System, Volume 2. Tumors of the Central Nervous System, vol 2. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-0618-7_8
Download citation
DOI: https://doi.org/10.1007/978-94-007-0618-7_8
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-0617-0
Online ISBN: 978-94-007-0618-7
eBook Packages: MedicineMedicine (R0)